Final results of the prospective biomarker trial PETra: [¹¹C]-MET-accumulation in postoperative PET/MRI predicts outcome after radiochemotherapy in glioblastoma

Central Nervous System Tumors

MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: results from the randomized ARTE trial

Clin Cancer Res.

Wirsching HG, Roelcke U, Weller J, Hundsberger T, Hottinger AF, von Moos R, Caparrotti F, Conen K, Remonda L, Roth P, Ochsenbein AF, Tabatabai G, Weller M

doi: 10.1158/1078-0432.CCR-20-2096.

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Head and Neck CancerRadio-Oncology

Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial

Eur J Nucl Med Mol Imaging.

Nicolay NH, Wiedenmann N, Mix M, Weber WA, Werner M, Grosu AL, Kayser G

doi: 10.1007/s00259-019-04598-9.

Genitourinary Cancer

Incorporating MRI and biomarkers in active surveillance protocols - results from the prospective Stockholm3 Active Surveillance trial (STHLM3AS)

J Natl Cancer Inst.

Olsson H, Nordström T, Jäderling F, Egevad L, Vigneswaran HT, Annerstedt M, Grönberg H, Eklund M, Lantz A

doi: 10.1093/jnci/djaa131.

SPECIAL REPORT

Multiple Myeloma (MM)

Traitement du myélome multiple récidivant/réfractaire

COMMENTED

Genitourinary CancerRadio-Oncology

Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial

★ 2 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

JAMA Oncol

Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J

doi: 10.1001/jamaoncol.2021.3771

Genitourinary Cancer

Prostate Cancer Highlights from ASCO GU 2021: Cutting-Edge Results

healthbook TIMES Oncology Hematology

Alexander Meisel

doi: DOI: 10.36000/hbT.OH.2021.08.041

RECOMMENDED

Genitourinary Cancer

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial

JAMA Oncol.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA

doi: 10.1001/jamaoncol.

SPECIAL REPORT

Multiple Myeloma (MM)

Related content

MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: results from the randomized ARTE trial

Recent Developments in Metastatic Breast Cancer

Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial

Incorporating MRI and biomarkers in active surveillance protocols - results from the prospective Stockholm3 Active Surveillance trial (STHLM3AS)

Traitement du myélome multiple récidivant/réfractaire

Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial

Prostate Cancer Highlights from ASCO GU 2021: Cutting-Edge Results

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial

Therapie des rezidivierten/refraktären Multiplen Myeloms